The Global Impact of Underfunding Women’s Health
Bias and stigma are to blame for the way women’s health research has fallen behind, according to Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's Integrated Health and Valentina Sartori, Ph.D., the leader of the McKinsey Health Institute's Life Sciences Practice in Europe.
Women’s health research, including menopause research, is largely underfunded due to social stigma and because women’s bodies are still viewed through a male lens, according to industry experts Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's Integrated Health and Valentina Sartori, Ph.D., the leader of the McKinsey Health Institute's Life Sciences Practice in Europe.
On average, women spend 25% more of their lives in poorer health than men, according to a recent analysis by the World Economic Forum in collaboration with the McKinsey Health Institute. Additionally, female-only health conditions such as menopause accounted for only 4% of pharmaceutical pipelines. The research goes on to show that addressing these disparities could improve the quality of life for women and create new market opportunities, unlocking more than $1 trillion in global GDP.
“Women's health issues don't get funded as well as other medical conditions, and certainly not something that's in the reproductive realm of things,” Christmas said in a Managed Healthcare Executive interview. “There's a social stigma around aging, in particular for women, and some of that is reflected in how research dollars are awarded.”
Monica Christmas, M.D.
An international Menopause Priority Setting Partnership (MAPS) survey led by the University of Chicago Medicine asked women from 42 countries what their top three questions about menopause were. Results showed include questions about nonhormonal alternatives, helpful lifestyle changes and about sleep and cognitive challenges. The finalized 10 priorities were published in a Dec. 21 research letter in the Lancet.
“We have taken a lens that has not been tailored to the uniqueness right of the female body and applied the same concepts that have worked for men,” Sartori added. “We see data that shows for 100 menstruating women only 30, then are in menopause, and you're like, where have the other 70 gone? There is a significant misrepresentation, because there is limited diagnosis.”
Valentina Sartori, Ph.D.
The Growing Popularity of Non-hormonal Menopause Therapy
February 12th 2025Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.
Read More
The Long Term Cost of Major Menopause Misconceptions
February 5th 2025An overview of menopause taboo, the lingering effects of the Women’s Health Initiative study and what employers can do support their menopausal workers, according to Stephanie Faubion, M.D., director of the Mayo Clinic’s Center for Women’s Health and medical director of The Menopause Society.
Read More
